GleamWall
中文EN

AKTS Aktis Oncology, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2035832 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets13.8%
Debt / equity0.00x
Current ratio14.22x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$3.90M$3.38M$3.23M$1.58M$1.60M$1.45M
R&D expense$32.12M$25.28M$20.04M$16.47M$18.63M$15.86M
SG&A expense$6.53M$7.00M$5.90M$3.31M$3.94M$3.73M
Operating income-$34.75M-$28.90M-$22.71M-$18.20M-$20.96M-$18.14M
Net income-$29.94M-$24.14M-$18.32M-$15.53M-$18.07M-$14.98M
EBITDA-$33.75M-$28.00M-$22.05M-$17.60M-$20.36M-$17.66M
EPS (basic)-0.54-0.44-0.38-19.18-22.39-18.60
EPS (diluted)-0.54-0.44-0.38-19.18-22.39-18.60
Weighted avg. shares (diluted)55.65M55.30M48.63M809,765807,281805,821
Balance sheet
Cash & equivalents$68.32M$82.49M$371.63M$180.25M$110.22M$58.25M
Current assets$499.89M$524.54M$543.94M———
PP&E, net$15.37M$15.97M$15.29M———
Total assets$532.48M$557.60M$576.80M———
Current liabilities$35.16M$32.13M$27.91M———
Total liabilities$73.61M$72.76M$70.69M———
Shareholders' equity$458.87M$484.84M$506.11M-$132.39M-$118.20M-$101.56M
Shares outstanding53.91M53.45M53.40M———
Cash flow statement
Operating cash flow-$26.05M-$20.59M-$24.24M-$15.22M-$16.18M-$17.48M
Capital expenditure$772,000$1.26M$1.85M$2.00M$1.53M$1.89M
Free cash flow-$26.82M-$21.85M-$26.10M-$17.23M-$17.71M-$19.38M
Investing cash flow$10.17M-$268.71M$20.54M$85.23M$68.14M$39.04M
Financing cash flow$1.71M$156,000$337.55M$28,000$0-$468,000
Depreciation & amortization$1.00M$900,000$652,000$600,000$600,000$484,000
Stock-based compensation$3.45M$3.22M$3.02M$1.28M$1.52M$1.24M

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.